Several preclinical cancer models, including studies on endometrial cancers cell lines, have shown that insulin-sensitizers might act as anticancer agents in ovarian and endometrial cancers and their ability to act on a variety of pathways, with wide-ranging effects, should be taken into consideration. Here, INS is linked to endometrial cancer.